表皮生长因子受体
非小细胞肺癌
癌症研究
无进展生存期
表皮生长因子受体抑制剂
作者
Makoto Maemondo,Tatsuro Fukuhara,Haruhiro Saito,Naoki Furuya,Kana Watanabe,Shunichi Sugawara,Shunichiro Iwasawa,Yoshio Tsunezuka,Ou Yamaguchi,Morihito Okada,Kouzou Yoshimori,Ichiro Nakachi,Akihiko Gemma,Koichi Azuma,Koichi Hagiwara,Toshihiro Nukiwa,Satoshi Morita,Kunihiko Kobayashi
标识
DOI：10.1200/jco.2020.38.15_suppl.9506
摘要
9506Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we demonstrated the progress...
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
OsamaKareem
sinmon
GingerF
张欢馨
干净的琦
小安
畔畔
Nexus
科研狗
风清扬
Mic
风声3492881045
wulanshu
arniu2008
AllRightReserved
memory
433
lalala
乐空思
皖公网安备34019202002308
